文献速递主动脉疾病

开窗腔内修复与开放手术治近肾及肾旁主动脉瘤的多中心对比研究

A Multicentre Observational Cohort Study to Compare Short Term and Midterm Outcomes after Fenestrated Endovascular Aortic Repair and Open Surgical Repair in Juxtarenal and Pararenal Aortic Aneurysm: The FEORA Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-07-01

这项多中心回顾性队列研究纳入2017至2022年间五国十家中心714例择期修复近肾/肾旁主动脉瘤患者,比较开窗腔内修复(FEVAR,399例)与开放手术(OSR,315例)。FEVAR与OSR的30天死亡率和再干预率相似,但FEVAR总体再干预更多,倾向性评分匹配后总生存与免于重大再干预似乎相当。

要点

  • FEVAR与OSR的30天死亡率(1.5% vs 1.0%)和再干预率(9.0% vs 6.3%)相似。
  • FEVAR总体再干预风险更高(HR 4.40,95%CI 1.65-11.74),但非重大再干预或生存的预测因素。
  • 匹配队列中两种方法总生存与免于重大再干预似乎相当。

核心结论

  • FEVAR与OSR治疗择期近肾/肾旁主动脉瘤早期结果均优良。
  • FEVAR与总体再干预增加相关,但不是重大再干预或死亡的预测因素。
  • 在充分匹配的患者中,两种方法总生存和免于重大再干预似乎相当。

研究设计与样本

  • 多中心回顾性队列研究,纳入2017至2022年五国十家高容量中心连续择期修复近肾/肾旁主动脉瘤患者。
  • 共714例,FEVAR 399例(55.9%),OSR 315例(44.1%),采用1:1倾向性评分匹配调整基线差异。
  • 主要终点为中期死亡率和再干预,次要终点包括30天死亡率和再干预。

临床怎么用

  • 对于择期近肾/肾旁主动脉瘤,FEVAR和OSR均可作为选择,需结合患者情况个体化决策。
  • FEVAR术后需加强再干预监测,但重大再干预和生存与OSR可能相当。

局限性

  • 回顾性队列设计可能存在选择偏倚和未测量混杂。
  • 平均随访26.2个月,中期结果需更长期验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This multicentre, retrospective cohort study aimed compare fenestrated endovascular (FEVAR) with open surgical repair (OSR) for treatment of juxtarenal and pararenal aortic aneurysms (J/PAAA). METHODS: Consecutive patients undergoing elective repair of J/PAAA between 2017 - 2022 in ten high volume centres across five countries were examined. Primary endpoints were midterm mortality and re-intervention. Secondary endpoints included 30 day mortality and re-intervention. Propensity score matching (PSM; 1:1) was performed to adjust for baseline differences. The Strengthening the Reporting of Observational Studies in Epidemiology guidelines were followed. RESULTS: A total of 714 patients were included: 399 (55.9%) FEVAR and 315 (44.1%) OSR. Thirty day mortality (1.5% vs. 1.0%; p = .74) and re-interventions (9.0% vs. 6.3%; p = .21) were similar after FEVAR and OSR. Mean follow up was 26.2 months, without loss to follow up in either group. The 1, 3, and 5 year survival rates were 94.7%, 86.1%, and 71.7% after FEVAR vs. 95.6%, 90.3%, and 86.5% after OSR (p = .042). Re-intervention free survival at 1, 3, and 5 years was lower after FEVAR (89.2%, 81.4%, and 73.3% vs. 98.9%, 97.7%, and 96.3%; p < .001). Similarly, major re-intervention free survival was lower after FEVAR (96.6%, 92.3%, and 91.3% vs. 98.9%, 97.7%, and 96.3% after OSR; p = .045). FEVAR was identified as a predictor of all re-interventions (hazard ratio [HR] 4.40, 95% confidence interval [CI] 1.65 - 11.74; p = .003) but not major re-interventions (HR 2.44, 95% CI 0.98 - 6.04; p = .054) or survival (HR 1.8, 95% CI 0.92 - 3.60; p = .085) on Cox regression analysis. Cox regression analysis of the PSM cohorts confirmed similar results. CONCLUSION: Both FEVAR and OSR achieved excellent early outcomes for elective J/PAAAs. Although FEVAR was associated with increased overall re-interventions, it was not a predictor of major re-intervention or mortality. In adequately matched patients, overall survival, and freedom from major re-intervention appear comparable between approaches.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Becker D, Prendes CF, Bosiers MJ, et al. A Multicentre Observational Cohort Study to Compare Short Term and Midterm Outcomes after Fenestrated Endovascular Aortic Repair and Open Surgical Repair in Juxtarenal and Pararenal Aortic Aneurysm: The FEORA Study. Eur J Vasc Endovasc Surg. 2026. PMID: 42385842. doi:10.1016/j.ejvs.2026.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。